Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (25)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Smith, D. H.
Right arrow Articles by Bennett, C. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smith, D. H.
Right arrow Articles by Bennett, C. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:1590-1597, 2002
© 2002 European Society for Medical Oncology

Original Paper

A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK

D. H. Smith1,+, J. R. Adams2, S. R. D. Johnston4, A. Gordon3, M. F. Drummond5 and C. L. Bennett2,§

1 Kaiser Permanente Center for Health Research, Portland, OR; 2 Northwestern University and the Veterans Administration Hospital Lakeside, Chicago, IL; 3 Sammons Cancer Center, US Oncology, Dallas, TX, USA; 4 Royal Marsden Hospital, London; 5 The Centre for Health Economics, University of York, UK

Received 18 December 2001; Revised 3 April 2002; accepted 24 April 2002

Background:

Economic information is necessary for rational decision-making in health care. Many European countries require financial impact statements prior to drug approval, and many health care organizations in the USA consider cost-effectiveness when making formulary decisions. We report the findings and discuss the policy implications of an economic evaluation based on an international, randomized controlled trial of salvage therapy for epithelial ovarian cancer, wherein topotecan and pegylated liposomal doxorubicin (PLD) were found to have similar efficacy but differing toxicities.

Patients and methods:

Direct costs to the payer were estimated for 235 North American and 239 European trial participants who had relapsed or failed platinum-based therapy. Unit costs were obtained from national sources or previously reported economic analyses. Sensitivity analyses were also performed.

Results:

Total cost per person in the topotecan arm was $12 325 (95% CI $9445 to $15 415; P >0.05) higher in the USA-based analysis and $2909 (95% CI $779 to $3415; P <0.05) higher in the UK-based analysis than for PLD. Pegylated liposomal doxorubicin was cost saving over a wide range of assumptions. The main differences (per person) in toxicity management following PLD compared with topotecan in Europe were for blood transfusions ($1190 versus $181, respectively) and hospitalizations ($1197 versus $280, respectively). In North America, differences were mainly for granulocyte colony stimulating factors ($1936 versus $419 µg, respectively), erythropoietin ($3493 versus $308, respectively) and blood transfusions ($1346 versus $140, respectively).

Conclusions:

Policy makers who evaluate pharmacoeconomic studies should consider international differences in health care delivery. Cost assessments based on information obtained from one country may not be relevant for policy makers in a different country.

Key words: cost, economic analysis, ovarian cancer, PLD, topotecan


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
G. Ferrandina, M. Ludovisi, D. Lorusso, S. Pignata, E. Breda, A. Savarese, P. Del Medico, L. Scaltriti, D. Katsaros, D. Priolo, et al.
Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Progressive or Recurrent Ovarian Cancer
J. Clin. Oncol., February 20, 2008; 26(6): 890 - 896.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. E. Wolowacz, D. A. Cameron, H. C. Tate, and A. Bagust
Docetaxel in Combination With Doxorubicin and Cyclophosphamide As Adjuvant Treatment for Early Node-Positive Breast Cancer: A Cost-Effectiveness and Cost-Utility Analysis
J. Clin. Oncol., February 20, 2008; 26(6): 925 - 933.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. N.H. Timmer-Bonte, E. M.M. Adang, H. J.M. Smit, B. Biesma, F. A. Wilschut, G. P. Bootsma, T. M. de Boo, and V. C.G. Tjan-Heijnen
Cost-Effectiveness of Adding Granulocyte Colony-Stimulating Factor to Primary Prophylaxis With Antibiotics in Small-Cell Lung Cancer
J. Clin. Oncol., July 1, 2006; 24(19): 2991 - 2997.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. R. Adams, C. Angelotta, and C. L. Bennett
When the Risk of Febrile Neutropenia Is 20%, Prophylactic Colony-Stimulating Factor Use Is Clinically Effective, but Is It Cost-Effective?
J. Clin. Oncol., July 1, 2006; 24(19): 2975 - 2977.
[Full Text] [PDF]

Home page
 BloodHome page
N. Casadevall, P. Durieux, S. Dubois, F. Hemery, E. Lepage, M.-C. Quarre, G. Damaj, S. Giraudier, A. Guerci, G. Laurent, et al.
Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial
Blood, July 15, 2004; 104(2): 321 - 327.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
T. M. Allen and P. R. Cullis
Drug Delivery Systems: Entering the Mainstream
Science, March 19, 2004; 303(5665): 1818 - 1822.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.